Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
Más filtros

Medicinas Complementárias
Intervalo de año de publicación
1.
J. venom. anim. toxins incl. trop. dis ; 24: 25, 2018. graf, ilus
Artículo en Inglés | LILACS | ID: biblio-954850

RESUMEN

Autologous whole blood (AWB) administration is described as alternative/complementary medical practice widely employed in medical and veterinary therapy against infections, chronic pathologies and neoplasias. Our aim is to investigate in vivo biological effect of AWB using healthy murine models under the course of Trypanosoma cruzi acute infection. Methods: The first set of studies consisted of injecting different volumes of AWB and saline (SAL) into the posterior region of quadriceps muscle of healthy male Swiss mice under distinct therapeutic schemes evaluating: animal behavior, body and organ weight, hemogram, plasmatic biochemical markers for tissue damage and inflammatory cytokine levels and profile. To assess the impact on the experimental T. cruzi infection, different schemes (prior and post infection) and periods of AWB administration (from one up to 10 days) were conducted, also employing heterologous whole blood (HWB) and evaluating plasma cytokine profile. Results: No major adverse events were observed in healthy AWB-treated mice, except gait impairment in animals that received three doses of 20 µL AWB in the same hind limb. AWB and SAL triggered an immediate polymorphonuclear response followed by mononuclear infiltrate. Although SAL triggered an inflammatory response, the kinetics and intensity of the histological profile and humoral mediator levels were different from AWB, the latter occurring earlier and more intensely with concomitant elevation of plasma IL-6. Inflammatory peak response of SAL, mainly composed of mononuclear cells with IL-10, was increased at 24 h. According to the mouse model of acute T. cruzi infection, only minor decreases (< 30%) in the parasitemia levels were produced by AWB and HWB given before and after infection, without protecting against mortality. Rises in IFN-gamma, TNF-alpha and IL-6 were detected at 9 dpi in all infected animals as compared to uninfected mice but only Bz displayed a statistically significant diminution (p= 0.02) in TNF-alpha levels than infected and untreated mice. Conclusions: This study revealed that the use of autologous whole blood (AWB) in the acute model employed was unable to reduce the parasitic load of infected mice, providing only a minor decrease in parasitemia levels (up to 30%) but without protecting against animal mortality. Further in vivo studies will be necessary to elucidate the effective impact of this procedure.(AU)


Asunto(s)
Animales , Masculino , Ratas , Trypanosoma cruzi , Transfusión de Sangre Autóloga , Enfermedad de Chagas/sangre , Terapias Complementarias
2.
PLoS One ; 12(11): e0188550, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29176887

RESUMEN

Real-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD.


Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Nitroimidazoles/uso terapéutico , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Triazoles/uso terapéutico , Tripanocidas/uso terapéutico , Enfermedad de Chagas/sangre , Humanos , Monitoreo Fisiológico/métodos
4.
Antimicrob Agents Chemother ; 60(6): 3355-64, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27001816

RESUMEN

Although curcumin can increase the effectiveness of drugs against malaria, combination therapies using the molecule have never been investigated in Chagas disease (ChD). Therefore, we evaluated the efficacy of curcumin as a complementary strategy to benznidazole (Bz)-based chemotherapy in mice acutely infected with Trypanosoma cruzi Eighty-four 12-week-old Swiss mice were equally randomized into seven groups: uninfected (NI), T. cruzi infected and untreated (INF), infected and treated with 100 mg/kg of body weight Bz (B100), 50 mg/kg Bz (B50), 100 mg/kg curcumin (C100), 100 mg/kg Bz plus 100 mg/kg curcumin (B100 plus C100), and 50 mg/kg Bz plus 100 mg/kg curcumin (B50 plus C100). After microscopic identification of blood trypomastigotes (4 days after inoculation), both drugs were administered by gavage once a day for 20 days. Curcumin showed limited antiparasitic, anti-inflammatory, and antioxidant effects when administered alone. When curcumin and Bz were combined, there was a drastic reduction in parasitemia, parasite load, mortality, anti-T. cruzi IgG reactivity, circulating levels of cytokines (gamma interferon [IFN-γ], interleukin 4 [IL-4], and MIP1-α), myocardial inflammation, and morphological and oxidative cardiac injury; these results exceeded the isolated effects of Bz. The combination of Bz and curcumin was also effective at mitigating liver toxicity triggered by Bz, increasing the parasitological cure rate, and preventing infection recrudescence in noncured animals, even when the animals were treated with 50% of the recommended therapeutic dose of Bz. By limiting the toxic effects of Bz and enhancing its antiparasitic efficiency, the combination of the drug with curcumin may be a relevant therapeutic strategy that is possibly better tolerated in ChD treatment than Bz-based monotherapy.


Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Curcumina/uso terapéutico , Nitroimidazoles/uso terapéutico , Tripanocidas/uso terapéutico , Trypanosoma cruzi/patogenicidad , Enfermedad Aguda , Animales , Enfermedad de Chagas/sangre , Enfermedad de Chagas/inmunología , Citocinas/sangre , Citocinas/metabolismo , Femenino , Hígado/inmunología , Hígado/metabolismo , Ratones , Miocardio/inmunología , Miocardio/metabolismo , Parasitemia/sangre , Parasitemia/tratamiento farmacológico , Parasitemia/inmunología , Parasitemia/parasitología , Transaminasas/sangre , Trypanosoma cruzi/efectos de los fármacos , Trypanosoma cruzi/inmunología
5.
PLoS Negl Trop Dis ; 10(3): e0004528, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27002523

RESUMEN

An estimated 2 million inhabitants are infected with Chagas disease in Mexico, with highest prevalence coinciding with highest demographic density in the southern half of the country. After vector-borne transmission, Trypanosoma cruzi is principally transmitted to humans via blood transfusion. Despite initiation of serological screening of blood donations or donors for T. cruzi since 1990 in most Latin American countries, Mexico only finally included mandatory serological screening nationwide in official Norms in 2012. Most recent regulatory changes and segmented blood services in Mexico may affect compliance of mandatory screening guidelines. The objective of this study was to calculate the incremental cost-effectiveness ratio for total compliance of current guidelines from both Mexican primary healthcare and regular salaried worker health service institutions: the Secretary of Health and the Mexican Institute for Social Security. We developed a bi-modular model to analyze compliance using a decision tree for the most common screening algorithms for each health institution, and a Markov transition model for the natural history of illness and care. The incremental cost effectiveness ratio based on life-years gained is US$ 383 for the Secretary of Health, while the cost for an additional life-year gained is US$ 463 for the Social Security Institute. The results of the present study suggest that due to incomplete compliance of Mexico's national legislation during 2013 and 2014, the MoH has failed to confirm 15,162 T. cruzi infections, has not prevented 2,347 avoidable infections, and has lost 333,483 life-years. Although there is a vast difference in T. cruzi prevalence between Bolivia and Mexico, Bolivia established mandatory blood screening for T.cruzi in 1996 and until 2002 detected and discarded 11,489 T. cruzi -infected blood units and prevented 2,879 potential infections with their transfusion blood screening program. In the first two years of Mexico's mandated program, the two primary institutions failed to prevent due to incomplete compliance more potential infections than those gained from the first five years of Bolivia's program. Full regulatory compliance should be clearly understood as mandatory for the sake of blood security, and its monitoring and analysis in Mexico should be part of the health authority's responsibility.


Asunto(s)
Enfermedad de Chagas/sangre , Enfermedad de Chagas/epidemiología , Pruebas Serológicas/economía , Trypanosoma cruzi/aislamiento & purificación , Donantes de Sangre , Enfermedad de Chagas/prevención & control , Análisis Costo-Beneficio , Toma de Decisiones , Costos de la Atención en Salud , Humanos , Cadenas de Markov , México/epidemiología , Programas Nacionales de Salud , Sensibilidad y Especificidad , Reacción a la Transfusión
6.
Rev Inst Med Trop Sao Paulo ; 57(3): 245-50, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26200966

RESUMEN

INTRODUCTION: In order to examine the effectiveness of vitamin C (ascorbic acid) in combating the oxidative insult caused by Trypanosoma cruzi during the development of the chronic phase of Chagas disease, Swiss mice were infected intraperitoneally with 5.0 × 104 trypomastigotes of T. cruzi QM1strain. METHODS: Mice were given supplements of two different doses of vitamin C for 180 days. Levels of lipid oxidation (as indicated by thiobarbituric acid reactive substances-TBARS), total peroxide, vitamin C, and reduced glutathione were measured in the plasma, TBARS, total peroxide and vitamin C were measured in the myocardium and histopathologic analysis was undertaken in heart, colon and skeletal muscle. RESULTS: Animals that received a dose equivalent to 500 mg of vitamin C daily showed increased production of ROS in plasma and myocardium and a greater degree of inflammation and necrosis in skeletal muscles than those that received a lower dose or no vitamin C whatsoever. CONCLUSION: Although some research has shown the antioxidant effect of vitamin C, the results showed that animals subject to a 500 mg dose of vitamin C showed greater tissue damage in the chronic phase of Chagas disease, probably due to the paradoxical actions of the substance, which in this pathology, will have acted as a pro-oxidant or pro-inflammatory.


Asunto(s)
Antioxidantes/administración & dosificación , Ácido Ascórbico/administración & dosificación , Enfermedad de Chagas/tratamiento farmacológico , Suplementos Dietéticos , Animales , Biomarcadores/sangre , Enfermedad de Chagas/sangre , Enfermedad de Chagas/patología , Cromatografía Líquida de Alta Presión , Enfermedad Crónica , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Glutatión/sangre , Peroxidación de Lípido , Masculino , Ratones , Óxido Nítrico/sangre , Peroxidasa/sangre , Sustancias Reactivas al Ácido Tiobarbitúrico
7.
Rev. Inst. Med. Trop. Säo Paulo ; 57(3): 245-250, May-Jun/2015. tab
Artículo en Inglés | LILACS | ID: lil-752591

RESUMEN

Introduction: In order to examine the effectiveness of vitamin C (ascorbic acid) in combating the oxidative insult caused by Trypanosoma cruzi during the development of the chronic phase of Chagas disease, Swiss mice were infected intraperitoneally with 5.0 × 104 trypomastigotes of T. cruzi QM1strain. Methods: Mice were given supplements of two different doses of vitamin C for 180 days. Levels of lipid oxidation (as indicated by thiobarbituric acid reactive substances-TBARS), total peroxide, vitamin C, and reduced glutathione were measured in the plasma, TBARS, total peroxide and vitamin C were measured in the myocardium and histopathologic analysis was undertaken in heart, colon and skeletal muscle. Results: Animals that received a dose equivalent to 500 mg of vitamin C daily showed increased production of ROS in plasma and myocardium and a greater degree of inflammation and necrosis in skeletal muscles than those that received a lower dose or no vitamin C whatsoever. Conclusion: Although some research has shown the antioxidant effect of vitamin C, the results showed that animals subject to a 500 mg dose of vitamin C showed greater tissue damage in the chronic phase of Chagas disease, probably due to the paradoxical actions of the substance, which in this pathology, will have acted as a pro-oxidant or pro-inflammatory. .


Introdução: Para verificar a eficácia da vitamina C em combater o insulto oxidativo causado pelo Trypanosoma cruzi durante a evolução da fase crônica da doença de Chagas, camundongos Swiss foram previamente infectados via intraperitoneal com 5.0 × 104 tripomastigotas da cepa QM1 de T. cruzi. Métodos: Camundongos foram suplementados com duas diferentes doses de vitamina C por 180 dias. Foram mensurados os níveis de peroxidação lipídica (indicado por substâncias reativas ao ácido tiobarbitúrico-TBARS), peróxido total, vitamina C, e glutationa reduzida no plasma e TBARS, peróxido total e vitamina C no miocárdio, e foi realizado o estudo histopatológico em coração, cólon e músculo esquelético. Resultados: Animais que receberam diariamente uma dosagem equivalente a 500 mg de vitamina C apresentaram aumento na produção de ROS e RNS no plasma e no miocárdio e maior grau de inflamação e necrose em músculo esquelético em comparação àqueles que receberam doses menores ou nenhuma vitamina C. Conclusão: Embora muitas pesquisas tenham mostrado o efeito antioxidante da vitamina C, nossos resultados mostraram que os animais que foram expostos a 500 mg de vitamina C apresentaram maior dano tecidual na fase crônica da doença de Chagas, provavelmente devido a ações paradoxais desta substância, onde nesta patologia, poderá agir como pró-oxidante ou pró-inflamatória. .


Asunto(s)
Animales , Masculino , Ratones , Antioxidantes/administración & dosificación , Ácido Ascórbico/administración & dosificación , Enfermedad de Chagas/tratamiento farmacológico , Suplementos Dietéticos , Biomarcadores/sangre , Cromatografía Líquida de Alta Presión , Enfermedad Crónica , Enfermedad de Chagas/sangre , Enfermedad de Chagas/patología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Glutatión/sangre , Peroxidación de Lípido , Óxido Nítrico/sangre , Peroxidasa/sangre , Sustancias Reactivas al Ácido Tiobarbitúrico
8.
Braz. j. phys. ther. (Impr.) ; 19(3): 211-217, May-Jun/2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-751376

RESUMEN

Background: Hippotherapy uses horseback riding movements for therapeutic purposes. In addition to the horse's movement, the choice of equipment and types of floor are also useful in the intervention. The quantification of dynamic parameters that define the interaction of the surface of contact between horse and rider provides insight into how the type of floor surface variations act upon the subject's postural control. Objective: To test whether different types of surfaces promote changes in the amplitude (ACOP) and velocity (VCOP) of the center of pressure (COP) displacement during the rider's contact with the saddle on the horse's back. Method: Twenty two healthy adult male subjects with experience in riding were evaluated. The penetration resistances of asphalt, sand and grass surfaces were measured. The COP data were collected on the three surfaces using a pressure measurement mat. Results: ACOP values were higher in sand, followed by grass and asphalt, with significant differences between sand and asphalt (anteroposterior, p=0.042; mediolateral, p=0.019). The ACOP and VCOP values were higher in the anteroposterior than in the mediolateral direction on all surfaces (ACOP, p=0.001; VCOP, p=0.006). The VCOP did not differ between the surfaces. Conclusion: Postural control, measured by the COP displacement, undergoes variations in its amplitude as a result of the type of floor surface. Therefore, these results reinforce the importance of the choice of floor surface when defining the strategy to be used during hippotherapy intervention. .


Asunto(s)
Animales , Masculino , Transfusión Sanguínea/veterinaria , Enfermedad de Chagas/veterinaria , Huésped Inmunocomprometido , Macaca nemestrina/parasitología , Enfermedades de los Monos/parasitología , Trypanosoma cruzi/aislamiento & purificación , Anticuerpos Antiprotozoarios/sangre , Biomarcadores/sangre , Transfusión Sanguínea/efectos adversos , Enfermedad de Chagas/sangre , Enfermedad de Chagas/inmunología , Enfermedad de Chagas/transmisión , Fraccionamiento de la Dosis de Radiación , Terapia Genética , Modelos Animales , Macaca nemestrina/sangre , Macaca nemestrina/inmunología , Enfermedades de los Monos/sangre , Enfermedades de los Monos/inmunología , Trasplante de Células Madre , Trypanosoma cruzi/inmunología
9.
BMC Health Serv Res ; 15: 116, 2015 Mar 24.
Artículo en Inglés | MEDLINE | ID: mdl-25889097

RESUMEN

BACKGROUND: Integration of disease-specific programmes into the primary health care (PHC) service has been attempted mostly in clinically oriented disease control such as HIV/AIDS and tuberculosis but rarely in vector control. Chagas disease is controlled principally by interventions against the triatomine vector. In Honduras, after successful reduction of household infestation by vertical approach, the Ministry of Health implemented community-based vector surveillance at the PHC services (health centres) to prevent the resurgence of infection. This paper retrospectively analyses the effects and process of integrating a Chagas disease vector surveillance system into health centres. METHODS: We evaluated the effects of integration at six pilot sites in western Honduras during 2008-2011 on; surveillance performance; knowledge, attitude and practice in schoolchildren; reports of triatomine bug infestation and institutional response; and seroprevalence among children under 15 years of age. The process of integration of the surveillance system was analysed using the PRECEDE-PROCEED model for health programme planning. The model was employed to systematically determine influential and interactive factors which facilitated the integration process at different levels of the Ministry of Health and the community. RESULTS: Overall surveillance performance improved from 46 to 84 on a 100 point-scale. Schoolchildren's attitude (risk awareness) score significantly increased from 77 to 83 points. Seroprevalence declined from 3.4% to 0.4%. Health centres responded to the community bug reports by insecticide spraying. As key factors, the health centres had potential management capacity and influence over the inhabitants' behaviours and living environment directly and through community health volunteers. The National Chagas Programme played an essential role in facilitating changes with adequate distribution of responsibilities, participatory modelling, training and, evaluation and advocacy. CONCLUSIONS: We found that Chagas disease vector surveillance can be integrated into the PHC service. Health centres demonstrated capacity to manage vector surveillance and improve performance, children's awareness, vector report-response and seroprevalence, once tasks were simplified to be performed by trained non-specialists and distributed among the stakeholders. Health systems integration requires health workers to perform beyond their usual responsibilities and acquire management skills. Integration of vector control is feasible and can contribute to strengthening the preventive capacity of the PHC service.


Asunto(s)
Enfermedad de Chagas , Prestación Integrada de Atención de Salud , Vigilancia de la Población , Atención Primaria de Salud , Adolescente , Enfermedad de Chagas/sangre , Niño , Preescolar , Femenino , Conocimientos, Actitudes y Práctica en Salud , Honduras , Humanos , Masculino , Proyectos Piloto , Atención Primaria de Salud/organización & administración , Estudios Retrospectivos , Estudios Seroepidemiológicos , Servicio Social
11.
Infect Genet Evol ; 28: 245-50, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25448161

RESUMEN

The outbreak of acute Chagas disease due to oral transmission of the parasite is a well-known phenomenon mainly occurring in the Amazon. Such an event is described here for the first time in French Guiana. Eight patients of the same family, presenting epidemiological and clinical histories compatible with recent Trypanosoma cruzi infection of Chagas disease due to the ingestion of palm Oenocarpus bacaba juice were, rather late after the putative date of infection, underwent four parasitological and two serological specific tests for confirmation of the diagnosis. Real-time PCR results were positive for all the patients; strains were isolated by hemoculture from four patients, PCR identification of TcI DTU was made for six patients, while parasites were not detected in any of the patients by direct microscopic examination. The results of two serologic tests were positive. All patients were treated with benznidazole, and two patients were additionally given nifurtimox. A 6-year follow-up was possible for six patients. Real-time PCR was negative for these patients after 1 year, while the antibody rates decreased slowly and serology results were negative only after several years (1-5 years). Our findings confirm the occurrence of an outbreak of Chagas infection in members of the same family, with the oral mode of infection being the most likely hypothesis to explain this group of cases. Our results show the successful treatment of patients infected by TcI and the usefulness of real-time PCR for the emergency diagnosis of recent Chagas disease cases and in posttreatment follow-up.


Asunto(s)
Arecaceae/parasitología , Enfermedad de Chagas/diagnóstico , Enfermedad de Chagas/tratamiento farmacológico , Tripanocidas/administración & dosificación , Trypanosoma cruzi/aislamiento & purificación , Adolescente , Adulto , Anciano , Arecaceae/química , Enfermedad de Chagas/sangre , Enfermedad de Chagas/parasitología , Niño , Familia , Femenino , Guyana Francesa , Humanos , Masculino , Persona de Mediana Edad , Nifurtimox/administración & dosificación , Nitroimidazoles/administración & dosificación , Extractos Vegetales/química , Resultado del Tratamiento , Trypanosoma cruzi/clasificación
13.
Expert Rev Anti Infect Ther ; 11(9): 957-76, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24053276

RESUMEN

This article reviews the usefulness of various types of blood-derived biomarkers that are currently being studied to predict the progression of Chagas disease in patients with the indeterminate form, to assess the efficacy of antiparasitic drugs and to identify early cardiac and gastrointestinal damage. The authors used a search strategy based on MEDLINE, Cochrane Library Register for systematic review, EmBase, Global Health and LILACS databases. Out of 1716 screened articles, only 166 articles were eligible for final inclusion. The authors classified the biomarkers according to their biochemical structure and primary biological activity in four groups: i) markers of inflammation and cellular injury, ii) metabolic biomakers, iii) prothrombotic biomarkers and iv) markers derived from specific antigens of the parasite. Several potential biomarkers might have clinical potential for the detection of early cardiopathy. Such capacity is imperative in order to detect high-risk patients who require intensive monitoring and earlier therapy. Prospective studies with longer follow-ups are needed for the appraisal of biomarkers assessing clinical or microbiological cure after therapy. At the same time, studies evaluating more than one biomarker are useful to compare the efficacy among them given the lack of a recognized gold standard.


Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos/sangre , Enfermedad de Chagas/sangre , Enfermedad de Chagas/patología , Trypanosoma cruzi/efectos de los fármacos , Apolipoproteína A-I/sangre , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Citocinas/sangre , Progresión de la Enfermedad , Humanos , Inflamación , Miocardio/metabolismo , Miocardio/patología , Selenio/sangre , Troponina T/sangre , Tripanocidas/uso terapéutico , Trypanosoma cruzi/aislamiento & purificación , Trypanosoma cruzi/fisiología
14.
BMC Res Notes ; 5: 352, 2012 Jul 11.
Artículo en Inglés | MEDLINE | ID: mdl-22784664

RESUMEN

BACKGROUND: There is no published information about the use of different protocols to administer a highly diluted medication.Evaluate the effect of different protocols for treatment with biotherapic T. cruzi 17 dH (BIOT(Tc17dH)) on clinical/parasitological evolution of mice infected with T. cruzi-Y strain. METHODS: A blind, randomized controlled trial was performed twice, using 60 28-day-old male Swiss mice infected with T. cruzi-Y strain, in five treatment groups: CI - treated with a 7% ethanol-water solution, diluted in water (10 µL/mL) ad libitum; BIOT(PI) - treated with BIOT(Tc17dH) in water (10 µL/mL) ad libitum during a period that started on the day of infection; BIOT(4DI) - treated with BIOT(Tc17dH) in water (10 µL/mL) ad libitum beginning on the 4th day of infection; BIOT(4-5-6) - treated with BIOT(Tc17dH) by gavage (0.2 mL/ animal/day) on the 4th, 5th and 6th days after infection; BIOT(7-8-9) - treated with BIOT(Tc17dH) by gavage (0.2 mL/ animal/day) on the 7th, 8th and 9th days after infection. We evaluated: parasitemia; total parasitemia (P(total)); maximum peak of parasites; prepatent period (PPP) - time from infection to detection of the parasite in blood; patent period (PP) - period when the parasitemia can be detected in blood; clinical aspects; and mortality. RESULTS: Parasitological parameters in the BIOT(PI) and mainly in the BIOT(4PI) group showed better evolution of the infection compared to the control group (CI), with lower P(total), lower maximum peak of parasites, higher PPP, lower PP and longer survival times. These animals showed stable body temperature and higher weight gain and water consumption, with more animals having normal-appearing fur for longer periods. In contrast, groups BIOT(4-5-6) and BIOT(7-8-9) showed worse evolution of the infection compared to the control group, considering both parasitological and clinical parameters. The correlation analysis combined with the other data from this study indicated that the prepatent period is the best parameter to evaluate the effect of a medication in this model. CONCLUSIONS: The BIOT(4DI) group showed the best clinical and parasitological evolution, with lower parasitemia and a trend toward lower mortality and a longer survival period. The prepatent period was the best parameter to evaluate the effect of a medication in this model.


Asunto(s)
Antiparasitarios/farmacología , Productos Biológicos/farmacología , Terapia Biológica , Enfermedad de Chagas/tratamiento farmacológico , Homeopatía , Trypanosoma cruzi/efectos de los fármacos , Animales , Enfermedad de Chagas/sangre , Enfermedad de Chagas/parasitología , Enfermedad de Chagas/fisiopatología , Modelos Animales de Enfermedad , Masculino , Ratones , Parasitemia/tratamiento farmacológico , Factores de Tiempo , Trypanosoma cruzi/crecimiento & desarrollo
15.
Trends Parasitol ; 27(3): 102-5, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21212020

RESUMEN

Chagas disease, a neglected tropical disease discovered over 100 years ago, is caused by the intracellular parasite Trypanosoma cruzi and is most frequently associated with chronic cardiomyopathy and digestive disorders. Initial invasion of cells is followed by progressive inflammatory destruction of heart, muscles, nerves, and gastrointestinal (GI) tract tissue. Approximately 30% of patients progress to a chronic cardiomyopathy associated with increased morbidity and mortality. Seven to 10% of patients develop megasyndromes involving the GI tract, in particular, the esophagus and the colon. Results from several studies suggest that selenium (Se) deficiency could be an important factor in the pathogenesis of Chagas disease. In this opinion article, Se supplementation is proposed as an adjuvant therapy for treatment of chronic Chagas disease.


Asunto(s)
Antioxidantes/uso terapéutico , Enfermedad de Chagas/tratamiento farmacológico , Selenio/deficiencia , Selenio/uso terapéutico , Animales , Cardiomiopatía Chagásica/sangre , Cardiomiopatía Chagásica/tratamiento farmacológico , Enfermedad de Chagas/sangre , Quimioterapia Adyuvante , Progresión de la Enfermedad , Humanos , Ratones , Resultado del Tratamiento
16.
Int J Cardiol ; 145(1): 27-33, 2010 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-19625091

RESUMEN

Chronic chagasic cardiac patients are exposed to oxidative stress that apparently contributes to disease progression. Benznidazole (BZN) is the main drug used for the treatment of chagasic patients and its action involves the generation of reactive species. 41 patients with Chagas' heart disease were selected and biomarkers of oxidative stress were measured before and after 2 months of BZN treatment (5 mg/kg/day) and the subsequent antioxidant supplementation with vitamin E (800 UI/day) and C (500 mg/day) during 6 months. Patients were classified according to the modified Los Andes clinical hemodynamic classification in groups IA, IB, II and III, and the activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione S-transferase (GST) and glutathione reductase (GR), as well as the contents of reduced glutathione (GSH), thiobarbituric acid reactive species (TBARS), protein carbonyl (PC), vitamin E and C and nitric oxide (NO), myeloperoxidase (MPO) and adenosine deaminase (ADA) activities were measured in their blood. Excepting in group III, after BZN treatment SOD, CAT, GPx and GST activities as well as PC levels were enhanced while vitamin E levels were decreased in these groups. After antioxidant supplementation the activities of SOD, GPx and GR were decreased whereas PC, TBARS, NO, and GSH levels were decreased. In conclusion, BZN treatment promoted an oxidative insult in such patients while the antioxidant supplementation was able to attenuate this effect by increasing vitamin E levels, decreasing PC and TBARS levels, inhibiting SOD, GPx and GR activities as well as inflammatory markers, mainly in stages with less cardiac involvement.


Asunto(s)
Antioxidantes/uso terapéutico , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/metabolismo , Nitroimidazoles/efectos adversos , Estrés Oxidativo/efectos de los fármacos , Antioxidantes/farmacología , Ácido Ascórbico/sangre , Ácido Ascórbico/farmacología , Ácido Ascórbico/uso terapéutico , Enfermedad de Chagas/sangre , Enfermedad Crónica , Humanos , Estrés Oxidativo/fisiología , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo , Vitamina E/sangre , Vitamina E/farmacología , Vitamina E/uso terapéutico
17.
Parasitology ; 135(8): 943-53, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18598576

RESUMEN

Evolutionary and closer structural relationships are demonstrated by phylogenetic analysis, peptide prediction and molecular modelling between Solanum tuberosum apyrase, Schistosoma mansoni SmATPase 2 and Leishmania braziliensis NDPase. Specific protein domains are suggested to be potentially involved in the immune response, and also seem to be conserved during host and parasite co-evolution. Significant IgG antibody reactivity was observed in sera from patients with American cutaneous leishmaniasis (ACL) and schistosomiasis using potato apyrase as antigen in ELISA. S. mansoni adult worm or egg, L. braziliensis promastigote (Lb) and Trypanosoma cruzi epimastigote (EPI) have ATP diphosphohydrolases, and antigenic preparations of them were evaluated. In ACL patients, IgG seropositivity was about 43% and 90% for Lb and potato apyrase, respectively, while IgM was lower (40%) or IgG (100%) seropositivity for both soluble egg (SEA) and adult worm (SWAP) antigens was higher than that found for potato apyrase (IgM=10%; IgG=39%). In Chagas disease, IgG seropositivity for EPI and potato apyrase was 97% and 17%, respectively, while the IgM was low (3%) for both antigens. The study of the conserved domains from both parasite proteins and potato apyrase could lead to the development of new drug targets or molecular markers.


Asunto(s)
Apirasa/inmunología , Secuencia Conservada/inmunología , Mapeo Epitopo , Parásitos/enzimología , Parásitos/inmunología , Solanum tuberosum/enzimología , Secuencia de Aminoácidos , Animales , Anticuerpos Antiprotozoarios/inmunología , Apirasa/química , Enfermedad de Chagas/sangre , Enfermedad de Chagas/inmunología , Humanos , Leishmania braziliensis/enzimología , Leishmania braziliensis/genética , Leishmania braziliensis/inmunología , Leishmaniasis Cutánea/sangre , Leishmaniasis Cutánea/inmunología , Datos de Secuencia Molecular , Parásitos/genética , Filogenia , Estructura Terciaria de Proteína , Schistosoma mansoni/enzimología , Schistosoma mansoni/genética , Schistosoma mansoni/inmunología , Esquistosomiasis/sangre , Esquistosomiasis/inmunología , Alineación de Secuencia
18.
Vet Parasitol ; 153(3-4): 238-43, 2008 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-18337011

RESUMEN

Dehydroepiandrosterone (DHEA) enhances immune responses against a wide range of viral, bacterial, and parasitic pathogens. In a previous study, we reported that administration of DHEA significantly decreased the numbers of blood parasites in Trypanosoma cruzi experimental infection. The present study was undertaken to determine the effectiveness of DHEA in reducing the severity of acute phase T. cruzi infection of male and female Wistar rats. Animals were treated subcutaneously with 40 mg/kg body weight/day of DHEA. The concentration of nitric oxide (NO) was determined in spleen peritoneal cavity. Interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) were determined in the sera of uninfected and infected animals. DHEA treatment augments NO production for both sexes after in vitro LPS treatment for uninfected animals. Infection triggered enhanced NO levels although not significant. IL-2 and IFN-gamma were detectable in higher concentrations in treated and infected rats of both genders when compared to untreated controls. These data suggest that DHEA may have a potent immunoregulatory function that can affect the course of T. cruzi infection.


Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Enfermedad de Chagas/prevención & control , Deshidroepiandrosterona/uso terapéutico , Trypanosoma cruzi/efectos de los fármacos , Adyuvantes Inmunológicos/sangre , Animales , Enfermedad de Chagas/sangre , Enfermedad de Chagas/inmunología , Enfermedad de Chagas/parasitología , Deshidroepiandrosterona/sangre , Deshidroepiandrosterona/inmunología , Femenino , Interferón gamma/sangre , Interleucina-2/sangre , Masculino , Óxido Nítrico , Distribución Aleatoria , Ratas , Ratas Wistar , Índice de Severidad de la Enfermedad , Trypanosoma cruzi/patogenicidad
19.
Biol Pharm Bull ; 29(11): 2307-9, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17077535

RESUMEN

Ethanol extract from Arrabidaea triplinervia leaves showed in vitro activity (ED100 5.0 mg/ml) against trypomastigotes of Trypanosoma cruzi, the etiologic agent of Chagas; disease. Bioactivity-directed fractionation of this extract led to the isolation of ursolic and oleanolic acids as trypanocidal compounds besides pomolic acid (not tested) and alpinetine (inactive). A series of natural and synthetic derivatives of ursolic and oleanolic acids was simultaneously assayed for structure activity relationships (SAR) studies. Ursolic acid (ED100 0.4 mg/ml) was four times more active than oleanolic acid (ED100 1.6 mg/ml). The presence of free hydroxy and/or carboxy groups is necessary for the trypanocidal activity as could be deduced from the effect of the acetates, methyl ester, and aldehyde derivatives.


Asunto(s)
Bignoniaceae/química , Triterpenos/farmacología , Tripanocidas/farmacología , Animales , Enfermedad de Chagas/sangre , Enfermedad de Chagas/parasitología , Enfermedad de Chagas/prevención & control , Relación Dosis-Respuesta a Droga , Eritrocitos/efectos de los fármacos , Eritrocitos/parasitología , Espectrometría de Masas/métodos , Ratones , Estructura Molecular , Ácido Oleanólico/química , Ácido Oleanólico/aislamiento & purificación , Ácido Oleanólico/farmacología , Pruebas de Sensibilidad Parasitaria/métodos , Fitoterapia/métodos , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Hojas de la Planta/química , Relación Estructura-Actividad , Triterpenos/química , Triterpenos/aislamiento & purificación , Tripanocidas/química , Tripanocidas/aislamiento & purificación , Trypanosoma cruzi/efectos de los fármacos , Trypanosoma cruzi/crecimiento & desarrollo , Ácido Ursólico
20.
Antimicrob Agents Chemother ; 48(1): 69-74, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14693520

RESUMEN

The trypanocidal action of green tea catechins against two different developmental stages of Trypanosoma cruzi is reported for the first time. This activity was assayed with the nonproliferative bloodstream trypomastigote and with the intracellular replicative amastigote parasite forms. An ethyl acetate fraction from Camellia sinensis green tea leaves, which contains most of the polyphenolic compounds and the maximal trypanocidal activity, was obtained by fractionation of the aqueous extract with organic solvents. The active compounds present in this extract were further purified by LH-20 column chromatography and were identified by high-performance liquid chromatography analysis with a photo diode array detector and gas chromatography coupled to mass spectroscopy. The following flavan-3-ols derivatives, known as catechins, were identified: catechin, epicatechin, gallocatechin, epigallocatechin, catechin gallate, epicatechin gallate, gallocatechin gallate, and epigallocatechin gallate. The purified compounds lysed more than 50% of the parasites present in the blood of infected BALB/c mice at concentrations as low as 0.12 to 85 pM. The most active compounds were gallocatechin gallate and epigallocatechin gallate, with minimal bactericidal concentrations that inhibited 50% of isolates tested of 0.12 and 0.53 pM, respectively. The number of amastigotes in infected Vero cells decreased by 50% in the presence of each of these compounds at 100 nM. The effects of the catechins on the recombinant T. cruzi arginine kinase, a key enzyme in the energy metabolism of the parasite, were assayed. The activity of this enzyme was inhibited by about 50% by nanomolar concentrations of catechin gallate or gallocatechin gallate, whereas the other members of the group were less effective. On the basis of these results, we suggest that these compounds could be used to sterilize blood and, eventually, as therapeutic agents for Chagas' disease.


Asunto(s)
Camellia/química , Catequina/farmacología , Tripanocidas , Trypanosoma cruzi/efectos de los fármacos , Animales , Arginina Quinasa/metabolismo , Catequina/uso terapéutico , Enfermedad de Chagas/sangre , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Chlorocebus aethiops , Cromatografía de Gases , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Indicadores y Reactivos , Masculino , Ratones , Ratones Endogámicos BALB C , Extractos Vegetales/química , Extractos Vegetales/farmacología , Trypanosoma cruzi/enzimología , Células Vero
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA